Development of quantitative imaging biomarkers for assessing response to sarcoma

$257,109U54FY2015CANIH

Sarc, Ann Arbor MI

Investigators

Linked publications, trials & patents

Paper 37052491 Paper 36240209 Paper 36162051 Paper 33335088 Paper 33289920 Paper 32651460 Paper 32544094 Paper 31636198 Paper 31521948 Paper 31387924 Paper 31112524 Paper 30980399 Paper 30792533 Paper 30473623 Paper 30192230 Paper 29983640 Paper 29672864 Paper 29499154 Paper 29386236 Paper 29240584 Paper 29108279 Paper 29108227 Paper 28877055 Paper 28851813 Paper 28732326 Paper 28708250 Paper 28632504 Paper 28614716 Paper 28588009 Paper 28493547 Paper 28323337 Paper 28279710 Paper 28270683 Paper 28196207 Paper 28184331 Paper 27941796 Paper 27888797 Paper 27874193 Paper 27837031 Paper 27810924 Paper 27807188 Paper 27761835 Paper 27664537 Paper 27601584 Paper 27573658 Paper 27566104 Paper 27528222 Paper 27523972 Paper 27376027 Paper 27364557 Paper 27351911 Paper 27173057 Paper 27165358 Paper 27165356 Paper 27140314 Paper 27116634 Paper 27049730 Paper 27014915 Paper 26962161 Paper 26918731 Paper 26908627 Paper 26806808 Paper 26802024 Paper 26796306 Paper 26795289 Paper 26790525 Paper 26710211 Paper 26646755 Paper 26627009 Paper 26601204 Paper 26585554 Paper 26554828 Paper 26475335 Paper 26396249 Paper 26364859 Paper 26355893 Paper 26349414 Paper 26349011 Paper 26297069 Paper 26222502 Paper 26200462 Paper 26181268 Paper 26101897 Paper 26079799 Paper 26078988 Paper 26066736 Paper 26052443 Paper 26006023 Paper 25961935 Paper 25931818 Paper 25890085 Paper 25888633 Paper 25865047 Paper 25852058 Paper 25781619 Paper 25610746 Paper 25536954 Paper 25535838 Paper 25387699 Trial NCT02579980

Abstract

This translational research project will develop quantitative imaging bionnarkers for assessing therapeutic response in Sarcoma using advanced quantitative imaging approaches in PET and MRl. In Specific Aim #1, dynamic contrast enhanced (DCE) and diffusion weighted (DW) MRl will be evaluated in a multi-center clinical trial of patients with soft tissue sarcoma ofthe extremities receiving neoadjuvant chemotherapy prior to surgical resection. DCE- and DW-MRI imaging will be performed prior to and at the conclusion of chemotherapy to evaluate the correlation between treatment response assessed with MRl parameters (permeability, perfusion, and diffusion) and tumor histopathology obtained from surgical resection. Exploratory analysis will also be performed to compare imaging and pathologic response with clinical outcome. In Specific Aim #2, two novel PET apoptosis probes (18F-ML-10 and 1241-Diannexin) will be evaluated and compared to existing PET probes for glucose metabolism (FDG) and cellular proliferation (FLT). Similar strategies will be employed in Specific Aim #3 to evaluate hwo novel PET probes for angiogenesis (i8F-FPP(RgD) and 892R-beYaci?Ufnat)). Preclinical microPET/CT imaQlno studiQS will bQ performed in several sarcoma mouse models using the comprehensive panel of PET probes in longitudinal treatment studies of various therapeutic agents. Correlations with tumor histopathology will be performed to validate the imaging assessments. In addition, DCE and DW MRl imaging will be performed in the same studies to compare the more specific PET assessments of metabolism, proliferation, angiogenesis, and apopotosis with the MRl perfusion and diffusion measurements that are more clinically available. This will further refine and validate the interpretation of MRl imaging response measured in Specific Aim #1 as well develop more specific PET imaging probes for future clinical trials. Together, the Specific Aims of this proposal will advance bi-directional translational research that enhances the knowledge of clinical MRl biomarkers for assessing early drug response in sarcoma therapy (bedside to bench) as well as develop novel PET imaging agents that are translatable to clinical trials and patient care (bench to bedside).

View original record on NIH RePORTER →